1
|
Suphatsathienkul P, Sakpichaisakul K, Wechapinan T, Trachoo O, Virawan S, Wanitphakdeedecha R. Successful Treatment of Schwartz-Jampel Syndrome with Botulinum Toxin Type A. Dermatol Ther (Heidelb) 2024; 14:545-556. [PMID: 38285320 PMCID: PMC10890988 DOI: 10.1007/s13555-023-01088-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Accepted: 12/13/2023] [Indexed: 01/30/2024] Open
Abstract
Schwartz-Jampel syndrome (SJS) is a rare autosomal recessive disorder characterized by typical facial dysmorphism, generalized muscle stiffness, joint contracture, and skeletal abnormalities. This condition is caused by mutations in the heparan sulfate proteoglycan 2 (HSPG2) gene, which encodes perlecan, a component of the basement membrane. The management of patients with SJS primarily aims to alleviate symptoms related to muscle stiffness. In this report, we describe a male patient with SJS type 1A. Trio whole-exome sequencing identified a pathogenic mutation (NM_001291860.1: c.10897C>T; p.Arg3633Ter) and variants of unknown significance (NM_001291860.2: c.413+10G>T). The patient experienced difficulty in opening his eyes and mouth, which significantly limited his daily activities. Botulinum toxin A injection was administered and demonstrated significant clinical improvement after the treatment.
Collapse
Affiliation(s)
- Panittra Suphatsathienkul
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Kullasate Sakpichaisakul
- Division of Neurology, Department of Pediatrics, Ministry of Public Health, Queen Sirikit National Institute of Child Health, Bangkok, Thailand
- College of Medicine, Rangsit University, Bangkok, Thailand
| | - Thanin Wechapinan
- Division of Neurology, Department of Pediatrics, Ministry of Public Health, Queen Sirikit National Institute of Child Health, Bangkok, Thailand
- Ministry of Public Health, Neurological Institute of Thailand, Bangkok, Thailand
| | - Objoon Trachoo
- Centre for Medical Genomics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Sorawit Virawan
- Division of Neurology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | |
Collapse
|
2
|
The Multispecialty Toxin: A Literature Review of Botulinum Toxin. Plast Reconstr Surg Glob Open 2022; 10:e4228. [PMID: 35402123 PMCID: PMC8987218 DOI: 10.1097/gox.0000000000004228] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 01/31/2022] [Indexed: 11/26/2022]
Abstract
Botulinum toxin (BoNT) is a potent biological exotoxin produced from Clostridium botulinum. Although it was first used therapeutically to treat strabismus, its clinical role has since expanded rapidly over the years to include treatment of a variety of head and neck, gastrointestinal, urogenital, musculoskeletal, neurological, dermatological, and cosmetic disorders. The main purpose of this review is to provide a brief updated overview of the history, mechanism of action, and clinical applications of BoNT therapy across multiple medical specialties, including the most common adverse effects and recommended Botox dosages.
Collapse
|
3
|
Anandan C, Jankovic J. Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel) 2021; 13:toxins13010042. [PMID: 33430071 PMCID: PMC7827923 DOI: 10.3390/toxins13010042] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/30/2020] [Accepted: 01/05/2021] [Indexed: 12/17/2022] Open
Abstract
Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.
Collapse
|
4
|
Srinoulprasert Y, Wanitphakdeedecha R. Antibody-induced botulinum toxin treatment failure: A review and novel management approach. J Cosmet Dermatol 2020; 19:2491-2496. [PMID: 32702171 DOI: 10.1111/jocd.13637] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 07/19/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND Botulinum neurotoxin A (BoNT/A) has been used for cosmetic indications for many decades. Consumption of BoNT/A usage has been markedly increased for a few years. Even new formulations of BoNT/A to decrease immunogenicity have been released, repeated treatment to maintain efficacy outcome is inevitable and could finally provoke immune response. In the past, prevalence of botulinum treatment failure (BTF) in cosmetic indication was rare leading to less medical concern. Current decade, case reports on BTF, especially antibody-induced botulinum toxin treatment failure (ABTF), have been increasingly revealed and risk factors associated with ABTF have been intensively studied. AIMS In this article, we will review antibody-induced botulinum toxin treatment failure (ABTF), risk-associated ABTF, prevalence and recent case reports of ABTF, and new approach to deal with ABTF. METHODS Literature search was conducted using PubMed. The relevant literatures published between January 2000 and May 2020 concerning BTF and ABTF including investigation for ABTF were included and analyzed. RESULTS Possible causes of BTF were summarized. ABTF could be a tip of iceberg of BTF, its prevalence, and currently, 10-year case reports of ABTF were published evidence. Risk factors and investigation methods for ABTF were also summarized. Based on previous studies and our experience, novel approach to management of ABTF was described. CONCLUSION Effective management of BTF is to explore causes of treatment failure. Antibodies against BoNT/A complex could be one of many possibilities. Laboratory in vitro tests could be alternative tools to decrease adverse effect and rebooting immune responses in BTF patients.
Collapse
Affiliation(s)
- Yuttana Srinoulprasert
- Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | |
Collapse
|
5
|
Wanitphakdeedecha R, Kantaviro W, Suphatsathienkul P, Tantrapornpong P, Yan C, Apinumtham C, Srinoulprasert Y. Association Between Secondary Botulinum Toxin A Treatment Failure in Cosmetic Indication and Anti-Complexing Protein Antibody Production. Dermatol Ther (Heidelb) 2020; 10:707-720. [PMID: 32445175 PMCID: PMC7367960 DOI: 10.1007/s13555-020-00397-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Indexed: 11/30/2022] Open
Abstract
Introduction Botulinum toxin A (BoT/A) treatment failure (BTF) affects patients subjected to repeated BoT/A exposure for cosmetic indications. BoT/A’s general formulation contains core BoT/A and complexing proteins. BTF may be caused by antibody-induced treatment failure. Antibodies against core BoT/A can occur; however, anti-complexing protein antibodies have never been demonstrated, and tools for anti-complexing protein antibody detection have not been developed. The aim of this study was to evaluate immune involvement in BoT/A-nonresponsive patients. Methods Patients suspected of nonresponsiveness to BoT/A for cosmetic indications were recruited. All volunteers were categorized as BoT/A-responsive or BoT/A-tolerant according to frontalis testing with onabotulinumtoxinA (onaA). Twenty-two BoT/A-tolerant volunteers were recruited separately for frontalis testing with incobotulinumtoxinA (incoA). Anti-BoT/A and anti-complexing protein antibodies were quantified by special ELISA using sera from blood sampled before and after frontalis testing. Results Significantly higher levels of IgG against complexing protein were detected in onaA-tolerant sera but not in onaA-responders, leading to proposals that anti-complexing protein antibodies could cause onaA unresponsiveness. Some onaA-tolerant patients according to frontalis test with incoA were responsive to incoA. Newly developed absorption ELISA confirmed that incoA-responsive sera predominantly contained IgG against complexing proteins, whereas incoA-tolerant sera contained significant levels of IgG against core BoT/A. The presence of anti-complexing protein antibodies higher than 90.75% in sera of onaA-tolerant patients could respond to incoA. The ELISA technique might be employed as a tool to predict incoA responsiveness. Our frontalis testing after incoA treatment showed that anti-incoA IgG levels were not increased by incoA. Conclusions BoT/A-exposed patients may develop antibodies against core botulinum toxin and complexing proteins. Our study is the first to demonstrate that anti-complexing protein antibodies cause BTF. High levels of antibodies against complexing proteins can cause onaA unresponsiveness, although some patients were still incoA-responsive. Our developed ELISA to detect anti-complexing protein antibodies can determine whether onaA-tolerant patients respond to incoA without incoA frontalis testing.
Collapse
Affiliation(s)
| | - Watsachon Kantaviro
- Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Panittra Suphatsathienkul
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Ploypailin Tantrapornpong
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Chadakan Yan
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Chalermkwan Apinumtham
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Yuttana Srinoulprasert
- Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
| |
Collapse
|
6
|
|
7
|
Abstract
Dystonia is a difficult problem for both the clinician and the scientist. It is sufficiently common to be seen by almost all physicians, yet uncommon enough to prevent any physician from gaining broad experience in its diagnosis and treatment. Each case represents a difficult challenge even to the specialist. The basic scientist is faced with investigating a disorder that is without relevant animal models and which is so rare that obtaining suitable tissue for study is a major obstacle. Dystonia may be idiopathic, or associated with lesions from many sources, including a variety of rare diseases. If idiopathic, it may be genetically transmitted or sporadic. If genetically transmitted, it may be generalized or focal, with symptoms varying in different members of the same family. It may be refractory to treatment, or it may respond to any one of a number of individual drugs that have very different mechanisms of action. For idiopathic dystonias, no clear method of genetic transmission has been established and no consistent pathology identified.
Collapse
|
8
|
|
9
|
Termsarasab P, Tanenbaum DR, Frucht SJ. The phenomenology and natural history of idiopathic lower cranial dystonia. JOURNAL OF CLINICAL MOVEMENT DISORDERS 2014; 1:3. [PMID: 26788329 PMCID: PMC4676493 DOI: 10.1186/2054-7072-1-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 05/07/2014] [Indexed: 12/12/2022]
Abstract
Background Many patients with lower cranial dystonia (LCrD) are misdiagnosed, and recognition of this condition by general practitioners and dental health professionals is limited. Methods We define the phenomenology and natural history of idiopathic LCrD, presenting in 41 patients with the disorder, the largest series of these patients reported to date. Results Phenomenology of dystonia included lower cranial and pharyngeal involvement, jaw opening and jaw closing dystonia, and tongue dystonia. Of 25 newly described patients, 72% (18) were female, average age at onset was 56 years, and delay before correct diagnosis was 3.8 years (0-25 years, median 2 years). Eleven patients (44%) reported a precipitating event, the most common of which was recent dental work. Geste antagonistes were found in 18 patients (72%). Response to treatment was mixed, indicating an unmet therapeutic need. Conclusions Idiopathic LCrD is often missed and institution of effective therapy is often delayed. The clinical features and natural history of LCrD are similar to other forms of focal dystonia. Electronic supplementary material The online version of this article (doi:10.1186/2054-7072-1-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Pichet Termsarasab
- Department of Neurology, Movement Disorders Division, Icahn School of Medicine at Mount Sinai, 5 East 98th St, first floor, New York, NY 10029 USA
| | - Donald R Tanenbaum
- Department of Neurology, Movement Disorders Division, Icahn School of Medicine at Mount Sinai, 5 East 98th St, first floor, New York, NY 10029 USA
| | - Steven J Frucht
- Department of Neurology, Movement Disorders Division, Icahn School of Medicine at Mount Sinai, 5 East 98th St, first floor, New York, NY 10029 USA
| |
Collapse
|
10
|
Khan TT, Herne K, Dayan SH, Woodward JA. Facial Blanching Due to Neurotoxins: Proposed Mechanisms. Dermatol Surg 2013; 39:24-9. [DOI: 10.1111/dsu.12057] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
11
|
Winterhoff J, Köhler S, Laskawi R. [Botulinum toxin for the treatment of spastic entropion. Case report]. HNO 2012; 61:665-7. [PMID: 23247753 DOI: 10.1007/s00106-012-2626-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Spastic entropion is a rare condition that predominantly affects older people. We report on a 74-year-old dementia patient who was successfully treated by botulinum toxin injections into the lower eyelid, thereby avoiding lid correction surgery. For patients with an increased risk of eyelid surgery, symptomatic therapy comprising botulinum toxin injections to the lower eyelid should be considered as an alternative treatment.
Collapse
Affiliation(s)
- J Winterhoff
- Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Göttingen.
| | | | | |
Collapse
|
12
|
Abstract
Introduction: Botox® (serotype A) is currently available and used to treat various ophthalmological conditions. The aim of our study was to review the current indications, side-effects and updates on the clinical use of botulinum toxin- A (Btx-A) in the field of ophthalmology. Methods: A literature search using the keywords “Botulinum Toxin”, “Botulinum Toxin A”, “Botox” and “Ophthalmology” was performed using Pubmed. Articles describing the use of botulinum toxin A were selected and reviewed. Results: The uses of Btx-A in ophthalmology can be broadly classified into four categories: eyelid, strabismus, cosmetic and others. In the eyelid, it can be used to treat blepharospasm, hemifacial spasm, apraxia of lid opening or induce ptosis in lid retraction and exposure keratopathy. In strabismus management, it can be injected into overacting muscles to realign the eyes. For cosmesis, it can be used to relax facial muscles to reduce wrinkles while other indications include treatment of chronic dry eye, lacrimal hypersecretion and pain relief in acute angle closure attack. Complications of the injection include local effects like ecchymosis, pain or infection and spillover effects like ptosis, diplopia, lagophthalmos, mid facial weakness and dry eyes. Conclusion: The clinical application of botulinum toxin A in ophthalmology is extensive. When considering its application in clinical practice, one should be mindful of the indications, risks and benefits of the procedure. When properly delivered, its potential as an efficacious, minimally-invasive treatment modality can be maximised in patient management.
Collapse
Affiliation(s)
- Livia Teo
- Singapore National Eye Centre
- Singapore Eye Research Institute
| | - Elaine Chee
- Singapore National Eye Centre
- Singapore Eye Research Institute
| |
Collapse
|
13
|
Robiony M. Intramuscular Injection of Botulinum Toxin as an Adjunct to Total Joint Replacement in Temporomandibular Joint Ankylosis: Preliminary Reports. J Oral Maxillofac Surg 2011; 69:280-4. [PMID: 21055863 DOI: 10.1016/j.joms.2010.05.042] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2009] [Revised: 02/23/2010] [Accepted: 05/14/2010] [Indexed: 11/28/2022]
Affiliation(s)
- Massimo Robiony
- Department of Surgical Science, University of Udine, Udine, Italy.
| |
Collapse
|
14
|
Abstract
OBJECTIVE To determine whether the duration of relief from symptoms in patients with essential blepharospasm (EB) or hemifacial spasm (HFS) who receive serial treatments with botulinum toxin type A (BtA) changes over the long-term. METHODS Retrospective longitudinal comparative analysis. The main outcome measure is the mean duration of relief from symptoms after an injection with BtA. Participants included 34 patients who received 30 or more serial BtA treatments for facial dyskinesia (EB or HFS). Repeated measures and linear regression analyses were used to determine trends and the mean duration of relief from symptoms was compared between early (first ten effective treatments) and late (last ten treatments) sessions in each group. RESULTS In the EB group (18 patients), the mean duration of relief was 13.5 weeks for the early and 11.4 weeks for the late sessions (P = 0.04). In the HFS group (16 patients) the mean duration of relief was 12.4 weeks in both treatment periods (P = 0.91). The duration of relief had a small negative correlation with mean late session BtA dose in the EB group (P = 0.03) but no correlation in the HFS group (P = 0.12). CONCLUSIONS There was a trend towards a decreased duration of relief from symptoms in patients with EB over the long-term, but no changes for HFS. The treatment remains effective in relieving symptoms and signs for both conditions.
Collapse
|
15
|
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye (Lond) 2009; 24:600-7. [PMID: 19648904 DOI: 10.1038/eye.2009.192] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
PURPOSE To investigate the long-term effectiveness and safety of botulinum neurotoxin A (BoNT-A) treatment in patients with blepharospasm (BEB), hemifacial spasm (HFS), and entropion (EN) and to use for the first time two modified indexes, 'botulin toxin escalation index-U' (BEI-U) and 'botulin toxin escalation index percentage' (BEI-%), in the dose-escalation evaluation. METHODS All patients in this multicentre study were followed for at least 10 years and main outcomes were clinical efficacy, duration of relief, BEI-U and BEI-%, and frequency of adverse events. RESULTS BEB, HFS, and EN patients received a mean BoNT-A dose with a significant inter-group difference (P<0.0005, respectively). The mean (+/-SD) effect duration was statistically different (P=0.009) among three patient groups. Regarding the BoNT-A escalation indexes, the mean (+/-SD) values of BEI-U and BEI-% were statistically different (P=0.035 and 0.047, respectively) among the three groups. In BEB patients, the BEI-% was significantly increased in younger compared with older patients (P=0.008). The most frequent adverse events were upper lid ptosis, diplopia, ecchymosis, and localized bruising. CONCLUSIONS This long-term multicentre study supports a high efficacy and good safety profile of BoNT-A for treatment of BEB, HFS, and EN. The BEI indexes indicate a significantly greater BoNT-A-dose escalation for BEB patients compared with HFS or EN patients and a significantly greater BEI-% in younger vsolder BEB patients. These results confirm a greater efficacy in the elderly and provide a framework for long-term studies with a more flexible and reliable evaluation of drug-dose escalation.
Collapse
|
16
|
Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J COSMET LASER THER 2009; 9:186-92. [PMID: 17763029 DOI: 10.1080/14764170701411470] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Very few pharmaceutical preparations share an evolutionary history as remarkable as that of botulinum neurotoxin (BoNT). The exotoxin of the organism Clostridium botulinum, once feared as a terrible poison, has been reborn as a highly regarded and widely used therapeutic and aesthetic agent. In less than two decades since the report of the success of BoNT type A (BoNTA) in reducing glabellar lines, injection of this product has become the most common non-surgical cosmetic procedure performed in the USA and worldwide. In addition to temporarily eliminating rhytids by muscle weakening, other dermatologic applications of BoNTA include correcting facial asymmetries and treating hyperhidrosis. Although BOTOX is the most clinically substantiated and published of the BoNTA preparations, other BoNTA products, as well as a BoNT type B product, are available in some parts of the world, and others are in development.
Collapse
Affiliation(s)
- Jean Carruthers
- Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
| | | |
Collapse
|
17
|
Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol 2009; 16:392-8. [PMID: 19364366 DOI: 10.1111/j.1468-1331.2008.02507.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND PURPOSE To review the clinical characteristics and the long-term outcome of patients with hemifacial spasm (HFS) who received botulinum neurotoxin (BoNT) over the past 10 years. RESULTS A total of 108 patients received 665 treatments. Mean latency of clinical effect was 5.4 +/- 5.3 days for Botox and 4.9 +/- 4.6 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher after the injection of Dysport than Botox: 105.9 +/- 54.2 and 85.4 +/- 41.6 days respectively (P < 0.01). The percentage of treatment failures was 6.5% for Botox and 4.6% for Dysport (P > 0.05). The doses of Botox significantly increased over time (beta = 0.35, P < 0. 001) whilst Dysport dose remained unchanged (beta = 0.16, n.s.). The duration of clinical benefit slightly increased with Botox (beta = 0.12; P < 0.01), but remained constant for Dysport. Side effects occurred in 17.4% of treatments: 16.7% of patients who had received Botox, and in 19.7% who had received Dysport (P > 0.05). The most common side effects were palpebral ptosis and lacrimation; ptosis and lagophtalmos was more common in Dysport treatments (P < 0.005). CONCLUSIONS Both brands are effective and safe in treating HFS; efficacy is long-lasting. The differences in outcome and side effects confirm that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.
Collapse
Affiliation(s)
- A R Bentivoglio
- Istituto di Neurologia, Università Cattolica del Sacro Cuore, Roma, Italia.
| | | | | | | | | | | |
Collapse
|
18
|
Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 2009; 15:224-31. [PMID: 19384595 DOI: 10.1007/s12640-009-9023-3] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2008] [Revised: 11/22/2008] [Accepted: 11/22/2008] [Indexed: 11/28/2022]
Abstract
OBJECTIVES To compare the clinical characteristics and the long-term outcome of a large series of patients with blepharospasm (BS) treated with the two most used brands of BoNT-A over the last 15 years. METHODS We have reviewed the clinical charts of 128 patients with BS who received botulinum neurotoxin (BoNT) in 1341 treatments (Botox in 1009, Dysport in 332) over the last 15 years. RESULTS Mean dose per session was 34U +/- 15 for Botox and 152U +/- 54 for Dysport. Mean latency of clinical effect was 4.5 +/- 4.6 days for Botox and 5.0 +/- 5.7 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher for Dysport than Botox: 80.1 +/- 36.3 and 66.2 +/- 39.8 days, respectively (P < 0.01). In a six-point scale (0: no efficacy, 6: remission of BS), the mean efficacy of both treatments was 3.60 +/- 1.3; 3.51 +/- 1.4 (Botox) and 3.85 +/- 1.2 (Dysport), P < 0.01. The doses of Botox (beta = 0.40) and Dysport (beta = 0.16) were significantly increased over time. Side effects occurred in 325 out of 1341 treatments (24.2%): 21.8% of the patients who had received Botox, and in 31.6% of those who had received Dysport (P < 0.01). CONCLUSIONS Both brands are effective and safe in treating blepharospasm; efficacy is long lasting. The differences in outcome and side effects suggest that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.
Collapse
Affiliation(s)
- A R Bentivoglio
- Istituto di Neurologia Università Cattolica del Sacro Cuore Largo Agostino Gemelli, 8 - 00168 Rome, Italy.
| | | | | | | | | | | |
Collapse
|
19
|
Wabbels B, Förl M. Botulinumtoxin bei Überfunktion der Tränendrüse, spastischem Entropium und Oberlidretraktion bei endokriner Orbitopathie. Ophthalmologe 2007; 104:771-6. [PMID: 17823804 DOI: 10.1007/s00347-007-1592-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
After proximal facial nerve lesions, misrouting of nerve fibres may cause the phenomenon of crocodile tears. Transconjunctival injections of botulinum toxin in the palpebral part of the lacrimal gland are the treatment of choice. An initial dose of 2.5 U of toxin is recommended, and injections may be repeated after 6 months if symptoms reoccur. Botulinum toxin A is also a highly effective temporary treatment for involutional (spasmodic) entropion until surgery is performed. A dose of 10 U of botulinum toxin is injected in the pretarsal part of the lower lid near the eyelashes. Botulinum toxin treatment is also effective for dysthyroid upper eye lid retraction, especially in instable thyroid disease or mild retraction. Slight transient ptosis may occur in some cases. Depending on the amount of retraction, a dose of 5 or 7.5 U of toxin is injected into the subconjunctival space at the superior margin of the tarsal plate.
Collapse
Affiliation(s)
- B Wabbels
- Universitätsaugenklinik Bonn, Ernst-Abbe-Strasse 2, 53127 Bonn.
| | | |
Collapse
|
20
|
Park DJJ, Harrison AR. Oculoplastic applications of botulinum toxin. EXPERT REVIEW OF OPHTHALMOLOGY 2007. [DOI: 10.1586/17469899.2.4.571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
21
|
Weigl DM, Arbel N, Katz K, Becker T, Bar-On E. Botulinum toxin for the treatment of spasticity in children: attainment of treatment goals. J Pediatr Orthop B 2007; 16:293-6. [PMID: 17527109 DOI: 10.1097/bpb.0b013e328092562b] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Forty patients (mean age 5 years) with a spastic disorder treated by botulinum injections (53 sessions) were evaluated for functional outcome in terms of achievement of their individual predetermined goals of treatment, rated on a modified Goal Attainment Scale from 1 (worsening function) to 4 (improved gross motor function). At the 2-week follow-up, 40% had a score of 1, 33% a score of 2, and 13% a score of 3; 12% showed no functional change. Botulinum treatments failed to significantly improve the gross motor function in this patient group. Treatment goals and expectations should clearly be established beforehand.
Collapse
Affiliation(s)
- Daniel M Weigl
- Pediatric Orthopedic Unit, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel.
| | | | | | | | | |
Collapse
|
22
|
Canter HI, Kayikcioglu A, Aksu M, Mavili ME. Botulinum Toxin in Closed Treatment of Mandibular Condylar Fracture. Ann Plast Surg 2007; 58:474-8. [PMID: 17452828 DOI: 10.1097/01.sap.0000244987.68092.6e] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The topic of condylar injury in adults has generated more discussion and controversy than any other in the field of maxillofacial trauma. The treatment of condylar fractures in adults is still a highly debated theme. METHODS Patients with unilateral subcondylar or condylar neck fractures of the mandibula without any significant angulation of the condylar head were managed with closed-treatment protocol. Closed treatment was applied through the injection of 100 units of botulinum toxin A, diluted to a concentration of 20 IU/mL, into the muscles of mastication of the fractured side. Masseter and anterior fibers of temporalis muscles were reached through percutaneous extraoral route and 30 IU of the toxin was injected to each muscle. Additional 40 IU of the toxin was injected around the fractured bone fragments through transmucosal intraoral route to paralyze medial and lateral pterygoid muscles as much as possible. An asymmetric occlusal splint was applied for maxillomandibular fixation to restore the vertical height for 10 days. Functional therapy with intermaxillary guiding elastics was advocated for 2 months. RESULTS There were no complications related to either toxin injections or splint application procedures. The toxin was effective on all occasions. Fractured condylar process and ramus of the mandibula were in good approximation and remained in reduced positions. None of the patients had any occlusal disturbance, mandibular asymmetry, or joint dysfunction in the follow-up period. CONCLUSIONS We believe that modification of treatment options concerning the clinical situation of the patients is the best method for condylar injury. The purpose of this study is to present and discuss the results achieved in closed treatment of a selected group of patients with mandibular condylar fractures to whom botulinum toxin A was injected to relieve the spasm of muscles of mastication, along with special splint application.
Collapse
Affiliation(s)
- Halil Ibrahim Canter
- Hacettepe University, Faculty of Medicine, Department of Plastic and Reconstructive Surgery, Ankara, Turkey.
| | | | | | | |
Collapse
|
23
|
Abstract
Since its introduction into clinical medicine in 1980, botulinum toxin has become a major therapeutic drug with applications valuable to many medical sub-specialties. Its use was spearheaded in ophthalmology where its potential applications have expanded to cover a broad range of visually related disorders. These include dystonic movement disorders, strabismus, nystagmus, headache syndromes such as migraine, lacrimal hypersecretion syndromes, eyelid retraction, spastic entropion, compressive optic neuropathy, and, more recently, periorbital aesthetic uses. Botulinum toxin is a potent neurotoxin that blocks the release of acetylcholine at the neuromuscular junction of cholinergic nerves. When used appropriately it will weaken the force of muscular contraction, or inhibit glandular secretion. Recovery occurs over 3 to 4 months from nerve terminal sprouting and regeneration of inactivated proteins necessary for degranualtion of acetylcholine vesicles. Complications are related to chemodenervation of adjacent muscle groups, injection technique, and immunological mechanisms.
Collapse
Affiliation(s)
- Jonathan J Dutton
- Department of Ophthalmology, University of North Carolina, Chapel Hill, NC 27599-7040, USA
| | | |
Collapse
|
24
|
Sami MS, Soparkar CNS, Patrinely JR, Hollier LM, Hollier LH. Efficacy of Botulinum Toxin Type A After Topical Anesthesia. Ophthalmic Plast Reconstr Surg 2006; 22:448-52. [PMID: 17117100 DOI: 10.1097/01.iop.0000248989.33572.3c] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE To determine whether the use of topical anesthesia has an impact on botulinum toxin type A (BTX-A) efficacy. METHODS Forty patients (20 receiving BTX-A for facial cosmetic rhytid reduction and 20 for benign essential blepharospasm) were evaluated in a double-blind, randomized, triple-crossover study at 2.5- to 4.5-month intervals. The discomfort and efficacy of BTX-A injections after betacaine application to half the face (random assignment) were compared against the discomfort and efficacy of a placebo ointment on the other half of the face. This was followed by cryoanalgesia to the entire face. RESULTS Patients ranged from 27 to 81 years of age (mean, 53 years), and 34 were female. Of the 120 total injection comparisons, a better BTX-A effect on one side of the face was reliably identified by 80% and 77% of blepharospasm and cosmetic patients, respectively, with the placebo-treated side providing better BTX-A effect approximately 90% of the time (p < 0.001). Patients reported a more painful side during injection in just 18 of the 120 trials, and only 1 of 40 patients believed the administration of analgesia was worth the trouble. CONCLUSIONS Pretreatment with topical betacaine followed by skin cooling seems to have a deleterious impact on BTX-A effect without a significantly beneficial patient-perceived reduction in injection discomfort.
Collapse
Affiliation(s)
- Mirwat S Sami
- Plastic Eye Surgery Associates, PLLC, Houston, Texas, USA
| | | | | | | | | |
Collapse
|
25
|
Carruthers J, Carruthers A. The Use of Botulinum Toxin Type A in the Upper Face. Facial Plast Surg Clin North Am 2006; 14:253-60. [PMID: 16908393 DOI: 10.1016/j.fsc.2006.04.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Jean Carruthers
- Department of Ophthalmology, University of British Columbia, 943 West Broadway, Suite 720, Vancouver, BC V5M 4E1, Canada.
| | | |
Collapse
|
26
|
Abstract
Schwartz-Jampel syndrome (SJS) is a rare congenital disorder of continuous myotonia, causing visual and eyelid problems such as blepharospasm, acquired ptosis, and blepharophimosis. We report the management of blepharospasm in two sisters with Schwartz-Jampel syndrome with application of botulinum toxin type A (BTX-A), as an alternative to the surgical treatments, such as orbicularis oculi myectomy, levator aponeurosis resection, and lateral canthopexy as described in the literature. Three consequent doses of commercially available BTX-A (Botox-Allergan, Inc. 100 u/via) were injected to orbicularis oculi muscle in two sisters with Schwartz-Jampel syndrome. At the least, the authors waited for a six-month interval to prevent development of sensitivity to BTX-A in patients. No significant improvement was observed after the injection of first dose of BTX-A, with the total dose of 25 units of BTX-A to each orbicularis oculi muscle of the eyes. The muscle tone weakened after the second dose, which was the twice as such of the first applied total dose (50 units of BTX-A to each orbicularis oculi muscle of the eyes) and significant functional and cosmetic improvements were achieved after injection of the third dose, in which the total applied dose was the same as the one applied in second dose. The blepharospasm and eyelid alterations caused by Schwartz-Jampel syndrome should be treated to provide functional and cosmetic improvements. Application of BTX-A to orbicularis oculi muscle for the treatment of blepharospasm could be considered as an alternative to levator resection, and lateral canthopexy in Schwartz-Jampel syndrome.
Collapse
Affiliation(s)
- Ibrahim Vargel
- Department of Plastic and Reconstructive Surgery, Kirikkale University Faculty of Medicine, Kirikkale, Turkey
| | | | | | | |
Collapse
|
27
|
Pang ALY, O'Day J. Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much? Clin Exp Ophthalmol 2006; 34:441-4. [PMID: 16872340 DOI: 10.1111/j.1442-9071.2006.01236.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Botulinum toxin (Botox) is the mainstay treatment for benign essential blepharospasm. Current treatment practice appears restricted by several reports demonstrating adverse effects and resistance to high-frequency, higher-dose therapy. This study aimed to explore whether high-dose, high-frequency treatments could be used without developing secondary resistance and without significant side-effects in patients refractory to conventional Botox doses. METHODS From a cohort of 120 patients being treated with Botox therapy for benign essential blepharospasm and idiopathic hemifacial spasm, case notes from six patients were retrospectively examined. In these patients, therapy had exceeded the recommended 50 units per side for a duration greater than 12 months and at less than 3 monthly intervals. Patterns in subjective severity grading and percentage of improvement as well as reported side-effects were analysed. RESULTS All patients described greater than 60% improvement and 0-2 severity grading over a 3- to 15-year period with no evidence of secondary resistance. Side-effects were minor, transient and less frequently reported at higher doses. CONCLUSION In a select group of patients, Botox therapy can be used effectively at doses higher than recommended over long periods with minimal side-effects and little evidence of secondary resistance.
Collapse
Affiliation(s)
- Anna L-Y Pang
- Department of Neurophthalmology, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
| | | |
Collapse
|
28
|
Dutton JJ, White JJ, Richard MJ. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Ophthalmic Plast Reconstr Surg 2006; 22:173-7. [PMID: 16714924 DOI: 10.1097/01.iop.0000217382.33972.c4] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
PURPOSE A small percentage of cases with essential blepharospasm or hemifacial spasm will become resistant to botulinum toxin A (Botox). We present our experience treating these patients with botulinum toxin B (Myobloc). METHODS We reviewed all charts of patients in one physician's practice who received botulinum toxin B after becoming refractory to botulinum toxin A. For each treatment session, patients were evaluated for side effects, relief of spasms, and duration of treatment effect. RESULTS Data were collected on 16 patients and a total of 93 treatment visits. Average total dosage was 3,633 U per treatment session. Mean duration of beneficial effect was 7.3 weeks and was most commonly rated as fair to excellent. Side effects for botulinum toxin B occurred at a higher rate than is typical for botulinum toxin A. Most common side effects were pain on injection (100%), ptosis (32.3%), facial or mouth droop (22.6%), dry mouth (17.2%), dry eye (9.7%), exposure keratitis (7.5%), and blurred vision (5.4%). The rate of occurrence of side effects appears to be dose-dependent. CONCLUSIONS Botulinum toxin B is a useful treatment for cases that have become refractory to botulinum toxin A. The duration of beneficial effect is shorter than for type A. The side effect profile is similar to that for toxin type A except for pain on injection and the occurrence of dry mouth. Side effects occurred at a higher frequency than with botulinum toxin A, and the pattern suggests that botulinum toxin B spreads more diffusely. Side effects appear to be dosage-related.
Collapse
|
29
|
Abstract
Until relatively recently, restoration of appearance by replacement of lost facial volume and muscular relaxation has been an illusory goal. With advances in the commercial availability of newer filling agents and a better understanding of the clinical esthetic effects of botulinum toxin A, remarkably sophisticated and refined results can now be achieved by using these noninvasive techniques. The combined use of BTX-A and filling agents, such as collagen and hyaluronic acid, can restore facial appearance by the dual mechanisms of reflation and relaxation. In addition, their combined use appears to increase the longevity of tissue dwell time of the filling agent. Current practices now strive to correct wrinkles by restoring volume and also relaxing the pull of muscles that create negative facial expressions such as glabellar folds, mouth frown, crow's feet, horizontal forehead lines, and perioral and cervical rhytides. As with any of the new technological innovations currently available, understanding of the differing properties of the agents used and education in optimal technique is essential to clinical and esthetic success.
Collapse
Affiliation(s)
- Kiersten R Coleman
- Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans, USA
| | | |
Collapse
|
30
|
Abstract
This article is structured around a literature review that was carried out using Ovid and Medline with the key words "botulinum," "toxin," and "ENT." Botulinum toxin has been used safely in humans for more than 20 years. The effects are transient, such that treatments are required to be repeated at intervals. Its application to ENT provides a useful tool to treat dystonia, autonomic dysfunction, facial nerve paresis, and hyperfunctional lines. It may also be of benefit in laryngeal rebalancing and the treatment of headaches. Further research is being carried out and new indications for treatment with botulinum toxin may include sialorrhea and rhinorrhea.
Collapse
|
31
|
Lee C, Kikkawa DO, Pasco NY, Granet DB. Advanced functional oculofacial indications of botulinum toxin. Int Ophthalmol Clin 2005; 45:77-91. [PMID: 15970767 DOI: 10.1097/01.iio.0000167165.25649.e7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Christina Lee
- Shiley Eye Center, MC 0946, University of California-San Diego, 9415 Campus Point Drive, La Jolla, CA 92093, USA
| | | | | | | |
Collapse
|
32
|
La exotoxina botulínica A en el tratamiento de las bandas del platisma. Plast Reconstr Surg 2004. [DOI: 10.1097/01.prs.0000124422.17493.1d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
La toxina botulínica A y la cirugía de las cefaleas. Plast Reconstr Surg 2004. [DOI: 10.1097/01.prs.0000124432.01353.9e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Connolly M, de Berker D. Management of primary hyperhidrosis: a summary of the different treatment modalities. Am J Clin Dermatol 2004; 4:681-97. [PMID: 14507230 DOI: 10.2165/00128071-200304100-00003] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Hyperhidrosis is a common and distressing condition involving increased production of sweat. A variety of treatment modalities are used to try to control or reduce sweating. Sweat is secreted by eccrine glands innervated by cholinergic fibers from the sympathetic nervous system. Primary hyperhidrosis most commonly affects palms, axillae and soles. Secondary hyperhidrosis is caused by an underlying condition, and treatment involves the removal or control of this condition. The treatment options for primary hyperhidrosis involve a range of topical or systemic medications, psychotherapy and surgical or non-surgical invasive techniques. Topical antiperspirants are quick and easy to apply but they can cause skin irritation and have a short half life. Systemic medications, in particular anticholinergics, reduce sweating but the dose required to control sweating can cause significant adverse effects, thus, limiting the medications' effectiveness. Iontophoresis is a simple and well tolerated method for the treatment of hyperhidrosis without long-term adverse effects; however, long-term maintenance treatments are required to keep patients symptom free. Botulinum toxin A has emerged as a treatment for hyperhidrosis over the past 5-6 years with studies showing good results. Unfortunately, botulinum toxin A is not a permanent solution, and patients require repeat injections every 6-8 months to maintain benefits. Psychotherapy has been beneficial in a small number of cases. Percutaneous computed tomography-guided phenol sympathicolysis achieved good results but has a high long-term failure rate. Surgery has also been shown to successfully reduce hyperhidrosis but, like other therapies, has several complications and patients need to be informed of these prior to undergoing surgery. The excision of axillary sweat glands can cause unsightly scarring and transthoracic sympathectomy (either open or endoscopic) can be associated with complications of compensatory and gustatory hyperhidrosis, Horner syndrome and neuralgia, some of which patients may find worse than the condition itself.
Collapse
Affiliation(s)
- Maureen Connolly
- Bristol Dermatology Centre, Bristol Royal Infirmary, Bristol, UK
| | | |
Collapse
|
35
|
Abstract
First used and approved over a decade ago for the treatment of strabismus (or misaligned eyes), botulinum toxin (BTX) has demonstrated efficacy in blepharospasm, hemifacial spasm, spastic lower eyelid entropion, and a number of other disorders seen in the traditional medical environment that are characterized by abnormal muscle contraction. Moreover, other conditions-notably some pain and gastrointestinal disorders-have responded to BTX injections.
Collapse
Affiliation(s)
- Jean Carruthers
- Department of Ophthalmology, University of British Columbia School of Medicine, Vancouver, British Columbia, Canada.
| | | |
Collapse
|
36
|
Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A Exotoxin for the Management of Platysma Bands. Plast Reconstr Surg 2003. [DOI: 10.1097/00006534-200310001-00026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
|
38
|
Snir M, Weinberger D, Bourla D, Kristal-Shalit O, Dotan G, Axer-Siegel R. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 2003; 136:99-105. [PMID: 12834676 DOI: 10.1016/s0002-9394(03)00075-8] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE To evaluate the quantitative changes in botulinum toxin A (BTA) treatment required over time to achieve relief for 3 to 4 months in patients with essential blepharospasm (EBS) and idiopathic hemifacial spasm (IHFS). DESIGN Interventional case series. METHODS In this retrospective longitudinal study in an institutional ophthalmologic outpatient clinic, data were retrieved from patient files and a comparison between patients with EBS and IHFS was performed. The patient population consisted of 27 patients, 17 with EBS and 10 with IHFS, who were treated for the first time with BTA injections and were followed up for 4 to 6 consecutive years. All patients initially received 12 or more courses of treatment with a lower dose (<or=20 U) and were then switched to a higher dose (>20 U). The main outcome measures were the shift in the dose-response relationship between the lower and higher doses and were analyzed with respect to four variables: average number of treatments, dosage, duration of therapy, and interval of symptomatic relief. RESULTS In the EBS group the mean dose for each patient changed from 16.0 +/- 1.4 U (lower dose) to 24.2 +/- 1.4 U (higher dose). The shift occurred after a mean of 8.8 +/- 2.9 treatments per patient given for a mean of 33.5 +/- 13.3 months. The mean interval of relief was longer with the lower dose than with the higher dose (4.0 +/- 1.4 months vs 3.2 +/- 1.0 months, respectively). In the IHFS group, the mean dose / patient changed from 16.8 +/- 1.2 U to 25.0 +/- 1.8 U, and the switch occurred after a mean of 6.5 +/- 2.3 treatments given over a mean period of 23.8 +/- 6.6 months. The mean duration of treatment with the lower dose was shorter than with the higher dose. The interval of relief was similar for both dose ranges (3.8 +/- 10 months and 4.1 +/- 1.3 months, respectively). The IHFS group switched to the higher dose earlier, by both number and duration of treatments, than the EBS group. Only minor and transient side effects of treatment were observed in both groups. CONCLUSIONS Botulinum toxin A is an effective and safe treatment for EBS and IHFS. The dose in our study was increased over time by 50% to achieve 3 to 4 months of symptomatic relief with minimal complications.
Collapse
Affiliation(s)
- Moshe Snir
- Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, Tel Aviv, Israel.
| | | | | | | | | | | |
Collapse
|
39
|
Abstract
This article reviews the cosmetic use of botulinum toxin in upper face from both the historic and clinical viewpoints. The published literature and our current experience are outlined. Botulinum toxin type A in the upper face has become an extremely popular cosmetic procedure and is outstandingly safe.
Collapse
|
40
|
Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. CANADIAN JOURNAL OF OPHTHALMOLOGY 2001; 36:398-403. [PMID: 11794389 DOI: 10.1016/s0008-4182(01)80084-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND Patients often ask whether the relief they experience with botulinum A toxin will diminish with time, resulting in the need for an increased dosage and more frequent administration. We performed a retrospective study to examine these questions. METHODS We reviewed the charts of 28 patients (17 with benign essential blepharospasm and 11 with hemifacial spasm) seen between 1989 and 1994 by one ophthalmologist at the botulinum clinic at a university-affiliated hospital in Edmonton. All patients had had at least 6 botulinum A toxin treatments; 17 had had 12 or more treatments, and 7 had had 20 or more treatments. A follow-up data collection form was used to record duration of effect, dosage and side effects. We analysed the data on duration of effect and dosage versus treatment number for individual patients and for the overall group using linear regression analysis. RESULTS There was no clinically or statistically significant change in duration of effect over time (mean slope 0.024 [95% confidence interval (CI) -0.218 to 0.266]). A positive mean slope of 0.677 (95% CI 0.252 to 1.102) was observed for the change in dosage over time. This trend was most likely related to the practitioner's habit of using half the normal maintenance dosage for the initial injection. When we eliminated the data for the first injection and recalculated the dosage requirement over time, the mean slope for the change in dosage was 0.321 (95% CI -0.084 to 0.726), confirming stable dosage requirements over time. INTERPRETATION The results suggest that patients can be reassured that duration of benefit and dosage requirements will likely remain stable over time for at least their first 20 treatments.
Collapse
Affiliation(s)
- G T Drummond
- Pediatric Ophthalmology and Adult Strabismus Unit, University of Alberta, Edmonton
| | | |
Collapse
|
41
|
Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 2001; 20:71-84. [PMID: 11474747 DOI: 10.1053/sder.2001.25138] [Citation(s) in RCA: 109] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This article reviews the cosmetic use of botulinum toxin in upper face from both the historic and clinical viewpoints. The published literature and our current experience are outlined. Botulinum toxin type A in the upper face has become an extremely poplular cosmetic procedure and is outstandingly safe.
Collapse
Affiliation(s)
- A Carruthers
- Department of Ophthalmology, University of British Columbia, Vancouver, Canada.
| | | |
Collapse
|
42
|
Affiliation(s)
- H A Khawaja
- Center for Dermatology and Cosmetic Surgery, San Salvador, El Salvador
| | | |
Collapse
|
43
|
Bashour M, Harvey J. Causes of involutional ectropion and entropion--age-related tarsal changes are the key. Ophthalmic Plast Reconstr Surg 2000; 16:131-41. [PMID: 10749160 DOI: 10.1097/00002341-200003000-00008] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE To measure tarsal plates across various age-groups, to determine whether tarsal size changes with increasing age and whether size correlates with involutional ectropion and entropion. METHODS Comparative, observational, case-control study design. Data were obtained for length and height of tarsus in each of the four eyelids. The data were constructed to determine: (I) right-to-left-side comparison data, (II) sex difference data, (III) age normal data, (IV) involutional entropion data, (V) involutional ectropion data. RESULTS (I) There is no difference in tarsal dimensions between right and left sides; (II) males have larger tarsal dimensions than females; (III) tarsal plates are on average smaller in older age ranges; (IV) patients with entropion have smaller than average age-normal tarsal plates; (V) patients with ectropion have larger than average age-normal tarsal plates. CONCLUSIONS (I) Right and left tarsal plates have equal dimensions, and involutional changes likely occur on both right and left sides equally frequently; (II) males have larger tarsal plates than females and entropion is more frequent in females and ectropion in males; (III) tarsal plates may have a general tendency to atrophy or shrink with age; this may explain why some eyelids develop entropion and others ectropion; (IV) entropion results from the mechanical effect of an atrophied or smaller than age-normal, partially or fully disinserted, tarsal plate being overcome by the normal or increased tone of the preseptal/pretarsal orbicularis muscle; (V) ectropion results from an age-normal or larger than normal tarsal plate mechanically overcoming the normal or decreased tone of the preseptal/pretarsal orbicularis muscle in combination with medial/lateral canthal tendon laxity.
Collapse
Affiliation(s)
- M Bashour
- Department of Ophthalmology, McGill University, Hamilton, Ontario, Canada
| | | |
Collapse
|
44
|
Affiliation(s)
- A V Benedetto
- Department of Dermatology, MCP Hahnemann University School of Medicine, Philadelphia, Pennsylvania, USA
| |
Collapse
|
45
|
Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 1999; 103:645-52; discussion 653-5. [PMID: 9950556 DOI: 10.1097/00006534-199902000-00043] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Injections of botulinum A exotoxin are successfully used to treat neuromuscular disorders and to improve hyperkinetic muscles and dynamic rhytids of the upper face. Using these principles, we extended its use to the treatment of the aging neck (hypertrophic platysma muscle bands). A classification system (I to IV) based on horizontal neck rhytids, platysma bands, and skin laxity was devised to categorize the degree of deformity and serve as a guideline for suggested dosages of botulinum. The results correlated with the degree of age-related neck degeneration. Type II (mild horizontal neck rhytids; thin, mild platysma muscle flaccidity; and mild skin laxity) and III (moderate horizontal neck rhytids; thick, moderate platysma muscle flaccidity; and moderate skin laxity) patients were the most satisfied, followed closely by types I and IV. A total of 1500 patients were treated by three independent practices. The majority of them achieved good-to-excellent results, as evaluated by both the physician and patient. The degree of muscle flaccidity and hypertrophy were the factors that most influenced success rates, not the anatomic variations in muscle configuration.
Collapse
Affiliation(s)
- A Matarasso
- Department of Plastic Surgery, Albert Einstein College of Medicine, and Manhattan Eye, Ear, and Throat Hospital, New York, NY, USA
| | | | | | | |
Collapse
|
46
|
Abstract
Patients who have exaggerated frown lines frequently ask for treatment because others mistake them to be constantly angry or annoyed. Current treatment options (surgery or implants) do not address the underlying cause of these lines, namely the excessive nerve stimulation. The mechanism of action of BTX makes it an ideal agent to target the major cause of these lines. BTX inhibits calcium metabolism in the presynaptic neuron, thereby inhibiting neuromuscular transmission and producing muscle paralysis. The current medical literature indicates that BTX can be used safely and effectively for the cosmetic treatment of frown lines. The procedure can be performed in an ambulatory setting and the use of an EMG instrument may provide better direction for the placement of the drug. However, the benefits are transient and repeated injections are necessary. The adverse effects associated with BTX injections were mild and transient. Currently, there are no safety data on the long-term effects of continuous BTX injections for the treatment of frown lines. However, studies on the long-term use of BTX at doses to treat blepharospasm and Meige's disease have shown no serious adverse effects or production of antibodies to BTX. Muscle biopsies taken from patients who have received numerous doses of BTX for more than 7 years have not shown any signs of atrophy or permanent muscle degeneration. The medical literature supports BTX therapy as an option for the treatment of cosmetic facial frown lines. However, there is not enough information on what patient characteristics are ideal in a candidate to achieve optimal response with BTX. Also, no data are available on the safety and efficacy of continuous injections in the long-term use of BTX for facial frown lines. Therefore, the use of BTX to treat frown lines should be examined carefully against other therapeutic options.
Collapse
Affiliation(s)
- K H Song
- Professional Product Information, Roche Laboratories, Inc., Nutley, NJ 07110, USA
| |
Collapse
|
47
|
Olver JM. Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. Br J Ophthalmol 1998; 82:528-33. [PMID: 9713061 PMCID: PMC1722612 DOI: 10.1136/bjo.82.5.528] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND/AIM Patients with thyroid eye disease with upper eyelid retraction often develop overaction of the accessory muscles of eyelid closure, the glabellar muscles corrugator supercilii and procerus. The resultant glabellar furrowing (frown lines) contributes to the typical thyroid facies. The aim of this study was to evaluate the use of botulinum toxin A reversible chemodenervation of the glabellar muscles as adjunctive treatment in the rehabilitation of patients with thyroid eye disease. METHODS 14 patients (13 females) ages 39-76 years (mean 52) with inactive thyroid eye disease and associated medial eyebrow ptosis and prominent glabellar frown lines were recruited. All patients had a history of upper eyelid retraction. Each patient was treated with a single botulinum toxin injection (Dysport 0.2 ml, 40 units) into each corrugator supercilii and sometimes procerus muscles as an outpatient procedure. The effectiveness and acceptability of the treatment was assessed clinically and from a patient questionnaire. RESULTS The injections were tolerated by 13/14 (93%) patients. There was resultant flattening of the glabellar region and improvement of medial eyebrow contour in all patients, with onset of paralysis within 1 week. All patients reported a subjective improvement in appearance. Side effects included one patient (7%) with reversible partial ptosis. The beneficial effect lasted 4-6 months, with a gradual return of function. Repeat treatment was indicated where there was persistent upper eyelid retraction and protractor overaction. CONCLUSION Botulinum toxin A chemodenervation of the glabellar muscles in these patients was effective and acceptable. Chemodenervation should be considered in the rehabilitation of patients with thyroid eye disease where there is upper eyelid retraction and overacting protractors resulting in a thyroid frown. Once the eyelid retraction has been successfully treated by surgery, the need for further glabella muscle chemodenervation is considerably reduced.
Collapse
|
48
|
Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996; 35:569-72. [PMID: 8859286 DOI: 10.1016/s0190-9622(96)90682-9] [Citation(s) in RCA: 104] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Botulinum A exotoxin (BTX) has been used successfully to treat a variety of hyperkinetic movement disorders. BTX is also capable of reducing hyperkinetic facial lines including prominent glabellar frown lines. OBJECTIVE The purposes of this study were to (1) confirm the efficacy of BTX in a double-blind, placebo-controlled investigation; (2) evaluate the use of an electromyogram attached to the injection needle to confirm intramuscular corrugator placement of the BTX; and (3) determine the optimum direction injection technique. METHODS Length and depth of glabellar frown lines were measured before treatment and 4 and 12 weeks after injection of 10 units of BTX or saline solution. RESULTS Patients treated with BTX had a highly significant reduction in depth and length of glabellar frown lines compared with control subjects. CONCLUSION BTX appears to be effective and safe for reduction of glabellar frown lines.
Collapse
Affiliation(s)
- N J Lowe
- Skin Research Foundation of California, Santa Monica, USA
| | | | | |
Collapse
|
49
|
Abstract
UNLABELLED There are conflicting reports concerning the variation in duration of symptoms relief for patients with hemifacial spasm who have undergone several injections of botulinum A toxin (BOTX-A). We present our experience of BOTX-A injections in Taiwanese patients to analyze this issues, and to inspect whether the efficacy of treatment depends on the pre-injection severity. MATERIAL AND METHOD From July 1992 to December 1994, 137 patients received injections of BOTX-A. We used objective and subjective score system to evaluate the efficacy and side effects of BOTX-A injection. RESULTS The overall successful rate of substantial relief of spasm was 88%. The mean duration of response was 20 weeks. Patents with more severe spasm tended to have shorter duration of improvement. The effects of consecutive injections remained fairly constant over the first 4 injections. CONCLUSION The BOTX-A injection is an effective and safe treatment for patients with hemifacial spasm and the effect could be sustained over the consecutive injections.
Collapse
Affiliation(s)
- R S Chen
- Department of Neurology, Chang Gung Memorial Hospital and Medical College, Taipei, Taiwan
| | | | | |
Collapse
|
50
|
Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996; 41:51-65. [PMID: 8827930 DOI: 10.1016/s0039-6257(97)81995-9] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Botulinum toxin has become the initial treatment of choice for the management of essential blepharospasm, hemifacial spasm and other craniocervical dystonias. Numerous studies have confirmed a 90% to 95% response rate. Although a number of common side effects have been reported, the occurrence and incidence of rare local complications remains poorly understood. More importantly, the acute and chronic distant effects of botulinum toxin have not been clearly elucidated. A better understanding of such effects is essential if clinicians are to appropriately advise patients on the use of this therapeutic modality. This article is based on the Duke University experience in the management of over 500 patients with craniocervical spasm disorders, combined with a review of the published literature. These disorders include essential blepharospasm, oromandibular dystonia, hemifacial spasm, and torticollis. The incidence of side effects following more than 6000 treatments with botulinum toxin is presented. Pertinent research relating to the causes of these complications is also reviewed. The most common complications of treatment with botulinum toxin are related to acute local effects resulting from chemodenervation. The most important clinical effect in this group is weakening of the levator muscle resulting in ptosis, and the corneal consequences of lagophthalmos. The latter includes exposure keratitis, dry eyes, blurred vision, and hypersecretion epiphora. Less common local effects include facial numbness, diplopia, and ectropion. Some distant effects are being observed with increasing frequency. These include pruritus, dysphagia, nausea, and a flu-like syndrome. Most significant, however, are the rare reports of generalized weakness and the documentation of EMG abnormalities distant to the site of toxin injection. This has been seen with injections for both blepharospasm and torticollis. Until further studies on the long-term distant complications of botulinum toxin are available, it is recommended that patients receive as few life-time doses of toxin as possible, consistent with adequate management of their spasms. The practice of reinjecting patients routinely every three months, or at the first return of mild spasms should be discouraged.
Collapse
Affiliation(s)
- J J Dutton
- Duke University Eye Center, Durham NC 27710, USA
| |
Collapse
|